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OBJECTIVES: Treprostinil is available in two forms (inhaled vs. infused) for the
treatment of patients with pulmonary arterial hypertension (PAH) and New York
Heart Association (NYHA) Class II-IV symptoms. The preference from 384 members
of the general public for the inhaled form, and this population’s willingness-to-pay
(WTP) in additional monthly insurance premiums for the inclusion of this treat-
ment on a hypothetical insurance scheme have been previously reported. The
present cost-benefit analysis (CBA) explored whether it would be cost-beneficial to
include inhaled treprostinil to a list of medications reimbursed by private third-
party payers in Canada, for PAH NYHA Class III patients. METHODS: The CBA was
based on a hypothetical population of 100,000. Total yearly benefits were calculated
by targeting subjects 18 years of age or older and active in the workforce, applying
the percentage of subjects who prefer inhaled treprostinil to infused treprostinil
(85.8%) and their median monthly WTP ($CAD21.50) multiplied by 12. Potential
costs were evaluated by estimating the number of potential PAH patients in the
hypothetical cohort, 18 years of age or older and in NYHA Class III category, mul-
tiplied by the annual cost of using inhaled treprostinil ($117,893). The final cost-
benefit to third-party payers was appraised by subtracting the potential costs from
the potential benefits. RESULTS: Based on prevalence rates, the hypothetical start-
ing cohort would yield 2 patients, resulting in expected costs of $235,786 to third-
party payers. The estimated number of subjects willing to pay for the inclusion of
inhaled treprostinil on the formulary of reimbursed drugs was 37,540, generating
benefits of $9,685,320. Hence, the expected difference (benefits minus costs) was
$9,449,534. CONCLUSIONS: The inclusion of inhaled treprostinil to formularies of
reimbursed medications would be highly cost-beneficial to private third-party pay-
ers in the province of Ontario, Canada, for patients with PAH and NYHA Class III
symptoms.
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OBJECTIVES: Fixed combinations of inhaled corticosteroids and long-acting 2-
agonists are widely used in treatment of patients with chronic obstructive pulmo-
nary disease (COPD) to reduce exacerbations. Cost-effectiveness analyses compar-
ing the costs and effects of the fixed combinations budesonide/formoterol and
fluticasone/salmeterol in COPD are scarce. The objective of this study was to eval-
uate the cost-effectiveness of budesonide/formoterol relative to fluticasone/sal-
meterol based on up to eleven years of real-world effectiveness data (NCT01146392)
from a Swedish health care perspective. METHODS: Resource use and effective-
ness data were collected retrospectively from primary care medical records’ data,
patients 18 years, both sexes, with a diagnosis of COPD (J44) and merged with
Swedish hospital, drug, and cause of death register data from 1 January 1999 to 31
December 2009. Propensity score matching of treatment groups was done at the
index date (first prescription of fixed combination post COPD diagnosis). Exacerba-
tions were defined as hospitalisations and emergency room visits for COPD, pre-
scription of glucocorticosteroids and/or prescription of antibiotics for respiratory
tract infections. Annual exacerbation rates were calculated using Poisson regres-
sion. The effectiveness variable was the number of exacerbations avoided. Direct
costs were calculated by applying year 2010 Swedish unit costs to the annual re-
source use. Bootstrapping was used to quantify uncertainty around estimates.
RESULTS: Based on 2734 patients in each treatment group, the annual exacerba-
tion rate was 0.800 for patients treated with budesonide/formoterol and 1.090 for
patients treated with fluticasone/salmeterol (26.6% reduction, p0.0001). Treat-
ment with budesonide/formoterol was found to be cost-saving compared with
treatment with fluticasone/salmeterol (total average annual per patient cost of
SEK12 580 [€1318] and SEK15 979 [€1675], respectively). CONCLUSIONS: Budes-
onide/formoterol was the dominant strategy (more effective at lower cost) com-
pared to fluticasone/salmeterol for the treatment of patients with COPD based on
11 years of real-world effectiveness data.
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OBJECTIVES: To estimate the cost-effectiveness of Beclomethasone/Formoterol
(BF) versus Fluticasone/Salmeterol (FS) in the treatment of adult out-patients with
moderate to severe asthma from the perspective of the Society in Spain.
METHODS: A Markov model was developed with five asthma health states: suc-
cessful control, sub-optimal control, outpatient-managed exacerbation, inpatient-
managed exacerbation, and death. Weekly transition probabilities were derived
from the published 12-weeks ICAT SE study. Resources utilization were obtained
from a published Spanish study designed ad-hoc to ascertain health care resources
utilization, the so-called lost-workday-equivalents, and corresponding costs re-
lated with treatment of asthma in the year 2011. Time horizon was set at 12 weeks
in the basecase scenario. Effectiveness was expressed as quality-adjusted life years
(QALY) gain. The cost-effectiveness was expressed as an incremental cost effec-
tiveness ratio (ICER). Bootstrapping techniques (10,000 re-samples) were used to
obtain the probabilistic ICER, its 95% percentile confidence interval (CI) and the
cost-effectiveness acceptability curve. Univariate and probabilistic sensitivity
analysis (PSA) were also applied and included, among others, extension of the
horizon to one year and the perspective of the NHS only. RESULTS: Compared with
FS, BF was associated with a slightly increase in QALY gain; 0,7974 vs. 0,7945 while
differential costs were always lower favoring BF and yielding to a mean ICER dom-
inant (95% CI: dominant; €46,930) per QALY gained. In 96% of re-samples, the ICER
was below the threshold of €30,000 per QALY, considered as cost-effective in Spain.
Univariate and PSA were robust and confirmed results of the basecase scenario.
CONCLUSIONS: From the Spanish societal and NHS perspectives in year 2011,
Becomethasone/Formoterol produced similar QALY gain at a lower cost when com-
pared with Fluticasone/Salmeterol in a highly meaningful number of replications
and scenarios. Thus, Beclomethasone/Formoterol may be considered a cost-effec-
tive alternative in the treatment of moderate to severe asthma in Spain.
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OBJECTIVES: To conduct comparative pharmacoeconomic analysis of
roflumilastformoterol versus formoterol monotherapy in adult patients with se-
vere-to-very severe COPD. METHODS: Analysis of the published clinical trials was
conducted to evaluate comparative efficacy and safety of the studied therapy op-
tions. Expected difference in direct medical costs was calculated in Excel model
based on clinical trial data about decreased number of exacerbations on
roflumilastformoterol therapy. 1-year costs of treatment were calculated from
the Russian health care system point of view. Parameter uncertainty was explored
using one-way sensitivity analysis. RESULTS: Patients on combination therapy
have 20.7% less exacerbations that leads to decreased costs of treatment. The
annual treatment cost per 1 patient was 37.93 USD less for roflumilastformoterol
therapy than for formoterol. The one-way sensitivity analysis showed that the
results are sensitive to the variations of key model parameters: for example com-
bination therapy remained the cheaper alternative when the price for roflumilast
was no more than  5.0-5.2% from the basic level. CONCLUSIONS: The combina-
tion of roflumilast  formoterol on average was more effective and cost-saving
treatment option for patients with severe-to-very severe COPD, but the results are
sensitive to the variations of price of roflumilast, the length of stay costs and the
duration of hospital stay for COPD exacerbations.
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OBJECTIVES: Austria’s smoking-rate is among the world highest. Varenicline has
been shown to be an effective and well-tolerated intervention for smoking cessa-
tion. The objective of this study was to evaluate and compare the cost-effective-
ness of varenicline with bupropion and nicotine-replacement-therapy (NRT) for
smoking cessation in Austria. METHODS: A markov-model was used to demon-
strate the Benefits of Smoking Cessation on Outcomes (BENESCO model). The
model simulates the incidence of four smoking-related morbidities: lung-cancer,
chronic-obstructive-pulmonary-disease, coronary-heart-disease and stroke. The
model computes costs, quality-adjusted-life-years (QALYs) and life-years (LYs)
gained. Incremental cost-utility-ratios were calculated, adopting a lifetime per-
spective. Efficacy data were obtained from a pooled varenicline phase 3a studies
(22.5% for varenicline and 15.7% for bupropion) and from Silagy(2005) for NRT
(15.5%). QALYs, life-years and costs were discounted at 5% p.a. RESULTS: The anal-
yses imply that for Austria, smoking cessation using varenicline versus budropion
or NRT is associated with reduced smoking-related morbidity and mortality. The
number of morbidities and mortalities avoided over lifetime, per 1000 smokers
attempting to quit, amounts to 7.36 cases of morbidities and 4.14 deaths if vareni-
cline is used instead of bupropion and 7.40 morbidities and 4.14 mortalities when
varenicline is used in place of NRT. The number of QALYs gained over lifetime, per
1000 smokers, was 16.64 (15.32 LYs gained) in case of varenicline vs. bupropion and
16.74 QALYs gained (15.40 LYs gained) for varenicline vs. NRT. The incremental
cost-utility-ratio of varenicline vs. bupropion amounts to 5,367€ and for varenicline
vs. NRT it is 4,070€. Additional costs were paid out-of-pocket. Probabilistic-sensi-
tivity-analyses demonstrated the robustness of the model regarding assumptions
and input-parameters. CONCLUSIONS: This cost-effectiveness analysis demon-
strated that varenicline treatment is cost-effective in Austria. Our results suggest
that funding varenicline as a smoking cessation aid is justifiable from a health care
resource allocation perspective.
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OBJECTIVES: To analyze the cost-effectiveness of Omalizumab in addition to Stan-
dard of Care (SoC) in the treatment of paediatric patients (6 yeas-old) with severe
uncontrolled asthma from the perspective of the Public Health Care System in
México. METHODS: A Markov model, with cycle duration of 2 weeks, was designed
to analyze the cost-effectiveness of Omalizumab vs SoC. Effectiveness was evalu-
ated by the number of exacerbations avoided. The model identifies 4 health-states,
and death based on symptoms and exacerbations with and without omalizumab.
Transition probabilities were obtained from two clinical studies identified after a
systematic review, with approximately 627 patients. Omalizumab showed a reduc-
tion of 43% in the asthma exacerbation rate vs SoC (Lanier, 2009). Model time
horizon was 20 years, with treatment duration of 6 years. A discount rate of 5% was
used for costs and outcomes. Direct medical costs associated with exacerbations
were elicited from an expert panel of clinicians and valuated by the unitary cost list
of the Mexican Institute of Social Security. Drug costs are those from public tenders
2012. (US$1MX$13.8). Probabilistic sensitivity analysis was performed using
Monte Carlo technique. RESULTS: The expected 20–year costs and number of ex-
acerbations per patient with each treatment were: Omalizumab US$96,483/31.52;
and SoC US$49,857/39.84. It represents 8.3 exacerbations avoided with an incre-
mental cost-effectiveness ratio of US$5,617 per exacerbation avoided for omali-
zumab versus SoC, below the Mexican threshold of 1GDP per-cápitaUS$8,586.
Probabilistic sensitivity analysis showed omalizumab was below the threshold 95%
of the times, according to the acceptability curve. The model is more sensitive to
changes in efficacy than price. CONCLUSIONS: For paediatric patients with severe
uncontrolled asthma, treatment with omalizumab is a cost-effective option com-
pared with current SoC in the health system. The higher drug acquisition cost of
Omalizumab is off-set by the lower rate of exacerbations seen with patients on
omalizumab and their related costs.
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OBJECTIVES: To assess the cost-effectiveness of adding omalizumab to standard
therapy (ST) alone in patients with uncontrolled severe allergic asthma from Bra-
zilian public health care system perspective. METHODS: A Markov model compar-
ing lifetime ST with omalizumab add-on therapy was developed based on efficacy
data from INNOVATE (Phase III trial, N419, 28 weeks). Outcomes are expressed as
clinically significant exacerbation (CSE) and clinically significant severe exacerba-
tion (CSSE) avoided. A CSE is defined in INNOVATE as worsening of asthma requir-
ing treatment with rescue systemic corticosteroids and a CSSE is defined as PEF/
FEV1 60% of personal best, in addition to requiring rescue treatment with
corticosteroids or requiring emergency room treatment or hospitalization. Re-
sources use data (physician consultations, laboratory tests, emergency rooms vis-
its, hospitalizations, drug treatments) was obtained from INNOVATE and valued
from the perspective of health care payer. In the model, subjects move back and
forth between daily symptoms (optimized asthma control) and the CSE or CSSE
states, as they have exacerbations and then recover. Patients can have several CSE
sequentially, or can remain with no exacerbation for a long period, determined by
the transition probabilities. The death states are separated into deaths from all
causes and asthma-related deaths due to severe exacerbations. One-way-sensitiv-
ity-analysis (OWSA) was performed. Annual discount rate of 5% was applied both
to costs and outcomes. RESULTS: Base case analysis showed that more CSE and
CSSE were avoided with omalizumab add-on therapy than ST alone (incremental of
17.57 and 9.27 respectively) with additional cost of BRL 122,392. Hence, omalizumab
ICERs are BRL 6,967/CSE avoided and BRL 13,198/CSSE avoided (1BRL0.487USD).
OWSA confirms the favorable results of base case for omalizumab. CONCLUSIONS:
The pharmacoeconomic evaluation confirms that omalizumab add-on therapy is
very cost-effective versus ST in the treatment of patients with uncontrolled severe
allergic asthma (i.e. 1GDP per capita or BRL 19,000; WHO threshold).
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OBJECTIVES: To estimate cost-effectiveness of montelukast in 2 – 6-year-old chil-
dren with mild-moderate persistent asthma in Belarus. METHODS: A one-year
decision tree model of asthma for a hypothetical cohort of 100 patients taking
either montelukast (4 mg/day) or budesonide inhalation suspension (0,5mg/day) or
lack of basis therapy has been constructed on the basis of the results of randomized
clinical studies and local data. The number and duration of asthma exacerbations,
the number of days with use of short-acting 2-receptor agonist (salbutamol) in-
haler, the number of salbutamol puffs per day have been calculated. Direct and
indirect costs have been calculated (U.S. $, 2012). The cost-effectiveness ratio (CER)
for montelukast, budesonide inhalation suspension or lack of basis therapy per
number of days without asthma attacks, exacerbations, use of short-acting 2-
receptor agonists has been quantified. Sensitivity analysis has been performed.
The duration and severity of asthma exacerbations, various types of pharmaco-
therapy were taken into consideration when sensitivity analysis was being made.
RESULTS: In 2 – 6-year-old children with mild-moderate persistent asthma the CER
of oral montedukast use was $4.1 per day without asthma attacks, exacerba-
tions, use of short-acting 2-receptor agonists, CER of budesonide inhalation
suspension use by nebulizer was $5.6, CER of lack of basis therapy was $6.9. The
resulting trend persisted during the sensitivity analysis. CONCLUSIONS: In Repub-
lic of Belarus the use of oral montelukast is considered to be cost-effective in
comparison to budesonide inhalation suspension or a lack of basis therapy in 2 –
6-year-old children with mild-moderate persistent asthma.
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OBJECTIVES:Global strategy for the prevention and treatment of bronchial asthma
(GINA) recommends antileukotriene drugs as second-line therapy, also while treat-
ing children. The cost-effectiveness analysis (CEA) of montelukast in 6-14-year-old
children suffering from mild-moderate persistent asthma has been performed to
determine economic advisability of its applying in Republic of Belarus. METHODS:
On the basis of the results of randomized studies and local data, the model of
asthma process for a hypothetical cohort of 100 patients taking either montelukast
(5 mg/day) or fluticasone - aerosol (250 mcg/day) has been constructed. The number
and duration of asthma exacerbations, the number of days with the use of short-
acting 2-receptor agonist (salbutamol) inhaler, the number of salbutamol puffs per
twenty-four hours have been chosen as important criteria influencing the process
of the disease and economic burden. RESULTS: In children older than 6 with mild-
moderate persistent asthma the priority medicine is an inhaled corticosteroid (ICS)
(CERfluticasone – 1, 45$ per day without attacks, aggravations, use of salbutamol as
compared to CERmontelukast – 2, 62$). The trends obtained in the main analysis
remain unchanged (CEAfluticasone – 1, 67$ for one day without attacks, aggravations,
use of salbutamol as compared to CEAmontelukast – 2, 98$) even if changes in the
period of hospitalization of the patients occur (an increase up to 14.7 days) as well
as in case of extension of exacerbation treatment or severity of exacerbation and
additional medical aid in the emergency room for one or two days. If indirect costs
caused by one of the parents’ absence at work are excluded from the analysis, the
priority medicine is an ICS: (CEAfluticasone – 1, 19$ as compared to CEAmontelukast – 1,
95$). CONCLUSIONS: In the Republic of Belarus inhaled corticosteroid is the prior-
ity medicine in children older than 6 years who are able to master the technique of
inhalation.
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OBJECTIVES: We hypothesized that one central laboratory would be more cost-
effective than several local laboratories because price of single Chlamylege test
depends on number of simultaneous tests performed. Incidence of pneumonia
requiring hospitalization in Poland is app.4/1000 persons/year. For hypothetical
population of one million people 4 000/ year will require hospitalization for pneu-
monia (VIP). We established seasonal incidence using clinical database of Military
Medical Institute Warsaw. New statistical method (Queuing Model)was used.
METHODS: Two simulation models were constructed for one million inhabitants:
one, where four hospital laboratories exist, performing 10-50 tests. Second, where
large central laboratory exists performing 50-200 tests. Three scenarios of morbid-
ity were established: 1) 3000 outpatients, 1000 inpatients, equal number of patients
over year; 2) 3000 outpatients, 1000 inpatients, number of patients/month related
to seasonality (4 seasons specified); 3) increased influx of patients: 12000 outpa-
tients and 4000 inpatients; number of patients/month related to seasonality.
RESULTS: 1) in central laboratory significantly smaller number of samples were
tested (mean 0.25vs0.75); 2) quarter 1 (increased patients influx) % tested in central
laboratory was significantly higher but still smaller than in the local labs
(0.92vs.0.95) whereas in quarter 3 (decreased patients influx) less tests per-
formed(0.2777 vs. 0.0005); and 3) % of tests made in central lab is much higher, but
still not exceeding number of tests performed in local labs ( 0.82vs.0.83). Central
laboratory performed less tests comparing to local labs and periods of inactivity
were noted which significantly increased cost of a single test. CONCLUSIONS: Ac-
cording to Queuing Model it was confirmed that creation of the central laboratory is
not reasonable in terms of costs. We conclude that Queuing Statistical Model can
be a useful tool for preliminary assessment ofthe cost-effectiveness of hypothe-
sized research methodology.
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OBJECTIVES: Clinical evidence shows that fewer infants fed for up to 4 months
with 100% partially hydrolyzed whey formula (pHF-W) subsequently develop
atopic dermatitis (AD) over up to 6 years than infants fed standard formula (SF) or
extensively hydrolyzed whey formula (eHF-W). The present study assessed the
cost-effectiveness of pHF-W compared to SF and eHF-W for the prevention of AD in
Germany. METHODS: A Markov cohort model was used to assess over a period of 6
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